Europe - Euronext Milan - BIT:DIA - IT0003492391 - Common Stock
The current stock price of DIA.MI is 74.86 EUR. In the past month the price increased by 19.07%. In the past year, price decreased by -27.93%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.13 | 105.86B | ||
| 1MDT.MI | MEDTRONIC PLC | 17.08 | 105.52B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 19.56 | 52.72B | ||
| 1SHL.MI | SIEMENS HEALTHINEERS AG | 19.62 | 52.88B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 17.32 | 24.69B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 17.24 | 24.57B | ||
| BIM.PA | BIOMERIEUX | 27.89 | 12.74B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 145.8 | 4.38B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 25.61 | 3.69B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 11.35 | 1.37B | ||
| DRW8.DE | DRAEGERWERK AG | 9.49 | 1.15B | ||
| ELN.MI | EL.EN. SPA | 22.11 | 1.14B |
DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The company is headquartered in Saluggia, Vercelli and currently employs 3,280 full-time employees. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
DIASORIN SPA
Via Crescentino Snc
Saluggia VERCELLI IT
Employees: 3279
Phone: 3901614871
DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The company is headquartered in Saluggia, Vercelli and currently employs 3,280 full-time employees. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
The current stock price of DIA.MI is 74.86 EUR. The price increased by 1.93% in the last trading session.
DIASORIN SPA (DIA.MI) has a dividend yield of 1.65%. The yearly dividend amount is currently 1.14.
DIA.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
DIA.MI stock is listed on the Euronext Milan exchange.
The Revenue of DIASORIN SPA (DIA.MI) is expected to grow by 0.83% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
DIASORIN SPA (DIA.MI) has a market capitalization of 4.19B EUR. This makes DIA.MI a Mid Cap stock.
ChartMill assigns a technical rating of 3 / 10 to DIA.MI. When comparing the yearly performance of all stocks, DIA.MI is a bad performer in the overall market: 89.43% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to DIA.MI. DIA.MI has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months DIA.MI reported a non-GAAP Earnings per Share(EPS) of 3.31. The EPS decreased by -5.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.87% | ||
| ROA | 6.56% | ||
| ROE | 12.26% | ||
| Debt/Equity | 0.35 |
18 analysts have analysed DIA.MI and the average price target is 88.17 EUR. This implies a price increase of 17.78% is expected in the next year compared to the current price of 74.86.
For the next year, analysts expect an EPS growth of 9.25% and a revenue growth 0.83% for DIA.MI